SIGHT (SIGHT) News
Follow SIGHT (SIGHT) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 4 public stories across 2 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
France's GenSight Biologics H1 net loss widens on higher R&D expenses
OverviewOutlookResult DriversCompany press release:Key DetailsAnalyst CoverageReuters Recommended ReadsFor questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feed
EARNINGS | Sep 29, 2026, 10:48 PM UTC
L
GenSight Biologics S.A. (SIGHT) Flags Going-Concern Risk; H1 Net Loss €10.3M
GenSight Biologics S.A. reported H1 2026 net loss of €10.3M, cash €1.7M at June 30, and a material going-concern uncertainty. It collected €6.5M cash from early access despite €(1.2)M reported revenue due to rebates and
NEWS | Sep 29, 2026, 10:37 PM UTC
L
GenSight Biologics Reports Interim Financial Results for the First Half of 2026 and Provides Business Updates
Regulatory News:GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases a
EARNINGS | Sep 29, 2026, 10:37 PM UTC
L
GenSight Biologics Provides September 2026 Business Updates
Regulatory News:GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases a
EQUITY | Sep 08, 2026, 05:30 AM UTC